19 completed, 6 terminated, 4 recruiting, 4 unknown. 37 Phase 2, 6 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Completed 19, Terminated 6, Recruiting 4, Unknown 4, Active not recruiting 2, Withdrawn 2 |
| Phase 3 | 6 | Completed 3, Unknown 3 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Diabetic Kidney Disease: new trials by email Literature Review of Diabetic Kidney Disease trials Research Report on Diabetic Kidney Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Formoterol in Diabetes Formoterol furmarate (20 μg) - Diabetic Nephropathies, Diabetic Kidney Disease | Phase 2 | Recruiting | Medical University of South Carolina | 120 | 2025-12-01 | 2026-02-05 |
| P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease 2HPβCD - Diabetic Kidney Disease | Phase 2 | Withdrawn | ZyVersa Therapeutics, Inc. | 2025-06-11 | 2025-11-25 | |
| The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease. R3R01, Placebo - Diabetic Kidney Disease | Phase 2 | Recruiting | River 3 Renal Corp. | 60 | 2024-10-10 | 2026-09-23 |
| Clinical Outcome of Vinpocetine in Diabetic Nephropathy Vinpocetine, Standard Therapy, Placebo - Diabetic Kidney Disease, Diabetic Nephropathies | Phase 2 / Phase 3 | Unknown | Ain Shams University | 64 | 2024-07-10 | 2024-07-11 |
| Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes Semaglutide, Placebo - Diabetic Kidney Disease, Type 1 Diabetes | Phase 2 | Recruiting | University of Washington | 60 | 2024-04-05 | 2026-06-02 |
| Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) Qishen Yiqi Dripping Pills placebo 3 bags, Low dose Qishen Yiqi Dripping Pills 3 bags, High dose Qishen Yiqi Dripping Pills 3 bags - Diabetic Kidney Disease | Phase 2 | Completed | Tasly Pharmaceutical Group Co., Ltd | 228 | 2023-09-15 | 2026-10-23 |
| Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib - Diabetic Kidney Disease | Phase 2 | Terminated | Iain Bressendorff | 1 | 2023-08-01 | 2024-09-25 |
| A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease Placebo of SC0062, SC0062 low dose, SC0062 medium dose - Diabetic Kidney Disease, IgA Nephropathy | Phase 2 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 255 | 2023-05-23 | 2025-01-07 |
| NAD Augmentation in Diabetes Kidney Disease Investigational Product - MIB 626, Placebo - Type2diabetes, Diabetic Kidney Disease | Phase 2 | Recruiting | Brigham and Women's Hospital | 156 | 2023-04-13 | 2026-04-13 |
| Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan - Diabetic Kidney Disease | Phase 2 | Completed | Shanghai Pharmaceuticals Holding Co., Ltd | 305 | 2023-03-22 | 2025-02-19 |
| Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics QRX-3 - Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease | Phase 2 | Completed | Ebima Clifford Okundaye | 127 | 2023-03-01 | 2025-09-08 |
| Mesenchymal Stem Cell Therapy in Diabetic Kidney Disease-A Double-blind, Placebo-controlled, Randomized Clinical Trial Mesenchymal stem cells, Normal Saline (Placebo) - Diabetic Kidney Disease | Phase 2 | Completed | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 78 | 2022-12-01 | 2025-06-26 |
| Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease INV-202, Placebo - Diabetic Kidney Disease | Phase 2 | Completed | Inversago Pharma Inc. | 265 | 2022-10-19 | 2025-08-11 |
| Renal Mechanism of SGLT2 Inhibition canagliflozin, Aminohippurate Sodium Inj 20% - Type 2 Diabetes, Diabetic Kidney Disease | Phase 2 | Active not recruiting | University of Colorado, Denver | 45 | 2022-10-10 | 2026-06-02 |
| SER150 vs Placebo in Diabetic Kidney Disease SER150, Placebo - Diabetic Kidney Disease | Phase 2 / Phase 3 | Completed | Serodus AS | 20 | 2021-08-18 | 2024-06-21 |
| A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels. BAY2327949, Placebo - Chronic Kidney Disease, Diabetic Kidney Disease | Phase 2 | Withdrawn | Bayer | 2021-05-31 | 2021-05-21 | |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
| Uric Acid Lowering Trial in Youth Onset T2D Pegloticase 8 MG/ML [Krystexxa] - Diabetic Kidney Disease, Hyperuricemia | Phase 2 | Completed | University of Colorado, Denver | 11 | 2020-01-01 | 2026-07-28 |
| A Phase 2b Diabetic Kidney Disease Study MEDI3506, Placebo, Dapagliflozin - Diabetic Kidney Disease | Phase 2 | Completed | AstraZeneca | 609 | 2019-11-18 | 2024-07-10 |
| Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy N Acetylcysteine - Diabetic Kidney Disease, Diabetes Mellitus, Type 2 | Phase 2 / Phase 3 | Unknown | Al-Azhar University | 60 | 2019-10-01 | 2020-08-28 |
Showing 20 of 37. Sign in to see all of them.
Diabetic Nephropathies (37) · Diabetes Mellitus, Type 2 (13) · Diabetes Mellitus (5) · Diabetes Mellitus, Type 1 (4) · Albuminuria (3) · Diabetes Complications (3) · Renal Insufficiency, Chronic (3) · Glomerulonephritis, IGA (2) · Kidney Diseases (2) · Disease Progression (1) · Glomerulosclerosis, Focal Segmental (1) · Hypertensive Nephropathy (1) · Hyperuricemia (1) · Kidney Failure, Chronic (1) · Nephritis, Hereditary (1)
Endocrine System Diseases (37) · Female Urogenital Diseases (37) · Female Urogenital Diseases and Pregnancy Complications (37) · Male Urogenital Diseases (37) · Urogenital Diseases (37) · Urologic Diseases (37) · Kidney Diseases (35) · Diabetes Complications (34) · Diabetes Mellitus (32) · Glucose Metabolism Disorders (16) · Metabolic Diseases (16) · Nutritional and Metabolic Diseases (16) · Pathological Conditions, Signs and Symptoms (9) · Autoimmune Diseases (6) · Immune System Diseases (6)
baricitinib (2) · p-Aminohippuric Acid (2) · semaglutide (2) · Acetylcysteine (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Atrasentan (1) · BMS-813160 (1) · Bariatric Surgery (1) · CME-1 polysaccharide, Cordyceps sinensis (1) · Canagliflozin (1) · Cholecalciferol (1) · Huang Qi (1) · Iohexol (1) · Pegloticase (1) · Pentoxifylline (1)
University of Colorado, Denver (4) · Bayer (2) · Eli Lilly and Company (2) · Gilead Sciences (2) · University of Washington (2) · Ain Shams University (1) · Al-Azhar University (1) · AstraZeneca (1) · Biocity Biopharmaceutics Co., Ltd. (1) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · Dimerix Bioscience Pty Ltd (1) · Ebima Clifford Okundaye (1) · Iain Bressendorff (1) · Inversago Pharma Inc. (1)
United States (21) · Canada (6) · Australia (5) · Denmark (5) · China (4) · Israel (3) · Italy (3) · Japan (3) · Austria (2) · Egypt (2) · Finland (2) · France (2) · Hungary (2) · Mexico (2) · New Zealand (2)
Petter Bjornstad, MD (2) · David Cherney, PhD, MD (1) · Giuseppe Remuzzi, MD (1) · Glenn Crater, MD (1) · Huda M. Salem, PhD (1) · Iain Bressendorff, MD PhD (1) · Ian H de Boer, MD, MS (1) · Ian de Boer, MD, MS (1) · Irl Hirsch, MD (1) · Jessica Kendrick, MD (1) · Jianghua Chen, Prof (1) · John Burkart, MD (1)
PMID 41805697, PMID 26180085, PMID 31506292, PMID 33184642, PMID 33436470, PMID 35369650, PMID 37254256, PMID 37560967, PMID 37783947, PMID 38299639, PMID 38682786, PMID 38770818, PMID 38810556, PMID 38899206, PMID 39018154, PMID 39462310, PMID 39899371, PMID 40693871, PMID 40938675, PMID 41442197, PMID 41563367, PMID 41708511, PMID 41866124, PMID 42603990
1KL2RR025015-01 (1), 2016 (1), 2017 (1), 2018 (1), P30DK017047 (1), R21AT002367 (1)